Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :
Indonesia merupakan negara dengan jumlah kasus dengue terbanyak dan terparah di Asia Tenggara Studi filogenetik virus dengue DENV diperlukan sebagai dasar pengembangan struktur vaksin yang cocok Meskipun demikian data sekuens DENV masih terbatas Penelitian ini bertujuan menganalisis sekuens dan filogenetik keseluruhan gen envelope DENV 1 dibandingkan dengan domain III saja Data didapatkan dari GenBank dan Laboratorium Mikrobiologi Fakultas Kedokteran Universitas Indonesia berupa whole genome DENV 1 sebanyak 30 sekuens yang diolah dengan Genetyx 5 1 Hasil analisis nukleotida gen envelope DENV 1 menunjukan strain Indonesia termasuk genotipe I dan IV Sedangkan analisis nukleotida dengan hanya domain III menunjukan adanya perbedaan cluster antar strain namun tetap dalam genotipe yang sama Dengan demikian studi filogenetik penentuan genotipe dapat dilakukan dengan hanya menggunakan domain III saja Analisis homologi asam amino domain III menunjukan epitope utama dilestarikan dan dapat menjadi landasan penting dalam pembuatan vaksin dengue berbasis domain III ...... Phylogenetic study of dengue virus DENV is required as a basis to develop a suitable structure for vaccine development Nonetheless DENV sequence data is limited This study aims to analyze and compare the sequence and phylogenetic of DENV 1 envelope gene with domain III The data is obtained from GenBank and Laboratory of Microbiology Faculty of Medicine Universitas Indonesia Thirty sequences of DENV 1 whole genome were processed using Genetyx 5 1 Analysis using DENV 1 envelope nucleotide showed that strain Indonesia has genotype I and IV Analysis using only the nucleotide of domain III showed the same genotype with difference of clusters between strains Thus phylogenetic studies determining the genotype can be done using domain III alone Homology analysis of amino acid of domain III showed that the main epitope is well reserved This finding can be an important cornerstone in the development of domain III based dengue vaccine.

Abstrak :
Background: a patient with a history of tuberculosis (TB) has a risk up to 27% to develop recurrence within 2 years after being cured. Indonesia itself has more than 7,500 recurrent cases annually, regardless of reinfection or relapse. This is an important problem, as recurrent TB is associated with lower cure rates with the anti-TB therapy and higher risk of developing drug resistance. Some risk factors for this recurrence are smoking, poor treatment adherence, low economic status, and weak immune status. This study is aimed to identify whether the use of fixed-dose combination (FDC) anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation. Methods: the search was conducted on MEDLINE, ProQuest, EBSCO, ScienceDirect, and Cochrane according to clinical question. The studies were selected based on inclusion and exclusion criteria and led to five useful articles. The selected studies were critically appraised for their validity, importance, and applicability. Results: five cohort studies were found with comparable validity. Only 1 study has accurate relative risk (RR) with 3.97 (1.14-13.80) and number needed to harm of 18. Other four studies fulfilled the applicability criteria for our case. Conclusion: the use of FDC anti-tuberculosis therapy increases the risk for tuberculosis recurrence compared with using separate drug formulation.